Proteolytic shedding of the prion protein via activation of metallopeptidase ADAM10 reduces cellular binding and toxicity of amyloid-β oligomers

The cellular prion protein (PrPC) is a key neuronal receptor for β-amyloid oligomers (AβO), mediating their neurotoxicity, which contributes to the neurodegeneration in Alzheimer's disease (AD). Similarly to the amyloid precursor protein (APP), PrPC is proteolytically cleaved from the cell surf...

Full description

Bibliographic Details
Main Authors: Jarosz-Griffiths, H, Corbett, N, Rowland, H, Fisher, K, Jones, A, Baron, J, Howell, G, Cowley, S, Chintawar, S, Cader, M, Kellett, K, Hooper, N
Format: Journal article
Language:English
Published: American Society for Biochemistry and Molecular Biology 2019
_version_ 1797096487876820992
author Jarosz-Griffiths, H
Corbett, N
Rowland, H
Fisher, K
Jones, A
Baron, J
Howell, G
Cowley, S
Chintawar, S
Cader, M
Kellett, K
Hooper, N
author_facet Jarosz-Griffiths, H
Corbett, N
Rowland, H
Fisher, K
Jones, A
Baron, J
Howell, G
Cowley, S
Chintawar, S
Cader, M
Kellett, K
Hooper, N
author_sort Jarosz-Griffiths, H
collection OXFORD
description The cellular prion protein (PrPC) is a key neuronal receptor for β-amyloid oligomers (AβO), mediating their neurotoxicity, which contributes to the neurodegeneration in Alzheimer's disease (AD). Similarly to the amyloid precursor protein (APP), PrPC is proteolytically cleaved from the cell surface by a disintegrin and metalloprotease, ADAM10. We hypothesized that ADAM10-modulated PrPC shedding would alter the cellular binding and cytotoxicity of AβO. Here, we found that in human neuroblastoma cells, activation of ADAM10 with the muscarinic agonist carbachol promotes PrPC shedding and reduces the binding of AβO to the cell surface, which could be blocked with an ADAM10 inhibitor. Conversely, siRNA-mediated ADAM10 knockdown reduced PrPC shedding and increased AβO binding, which was blocked by the PrPC-specific antibody 6D11. The retinoic acid receptor analog acitretin, which up-regulates ADAM10, also promoted PrPC shedding and decreased AβO binding in the neuroblastoma cells and in human induced pluripotent stem cell (iPSC)-derived cortical neurons. Pretreatment with acitretin abolished activation of Fyn kinase and prevented an increase in reactive oxygen species caused by AβO binding to PrPC. Besides blocking AβO binding and toxicity, acitretin also increased the nonamyloidogenic processing of APP. However, in the iPSC-derived neurons, Aβ and other amyloidogenic processing products did not exhibit a reciprocal decrease upon acitretin treatment. These results indicate that by promoting the shedding of PrPC in human neurons, ADAM10 activation prevents the binding and cytotoxicity of AβO, revealing a potential therapeutic benefit of ADAM10 activation in AD.
first_indexed 2024-03-07T04:42:33Z
format Journal article
id oxford-uuid:d224331f-e6c1-4d4a-bd56-75f2851078fd
institution University of Oxford
language English
last_indexed 2024-03-07T04:42:33Z
publishDate 2019
publisher American Society for Biochemistry and Molecular Biology
record_format dspace
spelling oxford-uuid:d224331f-e6c1-4d4a-bd56-75f2851078fd2022-03-27T08:01:55ZProteolytic shedding of the prion protein via activation of metallopeptidase ADAM10 reduces cellular binding and toxicity of amyloid-β oligomersJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d224331f-e6c1-4d4a-bd56-75f2851078fdEnglishSymplectic Elements at OxfordAmerican Society for Biochemistry and Molecular Biology2019Jarosz-Griffiths, HCorbett, NRowland, HFisher, KJones, ABaron, JHowell, GCowley, SChintawar, SCader, MKellett, KHooper, NThe cellular prion protein (PrPC) is a key neuronal receptor for β-amyloid oligomers (AβO), mediating their neurotoxicity, which contributes to the neurodegeneration in Alzheimer's disease (AD). Similarly to the amyloid precursor protein (APP), PrPC is proteolytically cleaved from the cell surface by a disintegrin and metalloprotease, ADAM10. We hypothesized that ADAM10-modulated PrPC shedding would alter the cellular binding and cytotoxicity of AβO. Here, we found that in human neuroblastoma cells, activation of ADAM10 with the muscarinic agonist carbachol promotes PrPC shedding and reduces the binding of AβO to the cell surface, which could be blocked with an ADAM10 inhibitor. Conversely, siRNA-mediated ADAM10 knockdown reduced PrPC shedding and increased AβO binding, which was blocked by the PrPC-specific antibody 6D11. The retinoic acid receptor analog acitretin, which up-regulates ADAM10, also promoted PrPC shedding and decreased AβO binding in the neuroblastoma cells and in human induced pluripotent stem cell (iPSC)-derived cortical neurons. Pretreatment with acitretin abolished activation of Fyn kinase and prevented an increase in reactive oxygen species caused by AβO binding to PrPC. Besides blocking AβO binding and toxicity, acitretin also increased the nonamyloidogenic processing of APP. However, in the iPSC-derived neurons, Aβ and other amyloidogenic processing products did not exhibit a reciprocal decrease upon acitretin treatment. These results indicate that by promoting the shedding of PrPC in human neurons, ADAM10 activation prevents the binding and cytotoxicity of AβO, revealing a potential therapeutic benefit of ADAM10 activation in AD.
spellingShingle Jarosz-Griffiths, H
Corbett, N
Rowland, H
Fisher, K
Jones, A
Baron, J
Howell, G
Cowley, S
Chintawar, S
Cader, M
Kellett, K
Hooper, N
Proteolytic shedding of the prion protein via activation of metallopeptidase ADAM10 reduces cellular binding and toxicity of amyloid-β oligomers
title Proteolytic shedding of the prion protein via activation of metallopeptidase ADAM10 reduces cellular binding and toxicity of amyloid-β oligomers
title_full Proteolytic shedding of the prion protein via activation of metallopeptidase ADAM10 reduces cellular binding and toxicity of amyloid-β oligomers
title_fullStr Proteolytic shedding of the prion protein via activation of metallopeptidase ADAM10 reduces cellular binding and toxicity of amyloid-β oligomers
title_full_unstemmed Proteolytic shedding of the prion protein via activation of metallopeptidase ADAM10 reduces cellular binding and toxicity of amyloid-β oligomers
title_short Proteolytic shedding of the prion protein via activation of metallopeptidase ADAM10 reduces cellular binding and toxicity of amyloid-β oligomers
title_sort proteolytic shedding of the prion protein via activation of metallopeptidase adam10 reduces cellular binding and toxicity of amyloid β oligomers
work_keys_str_mv AT jaroszgriffithsh proteolyticsheddingoftheprionproteinviaactivationofmetallopeptidaseadam10reducescellularbindingandtoxicityofamyloidboligomers
AT corbettn proteolyticsheddingoftheprionproteinviaactivationofmetallopeptidaseadam10reducescellularbindingandtoxicityofamyloidboligomers
AT rowlandh proteolyticsheddingoftheprionproteinviaactivationofmetallopeptidaseadam10reducescellularbindingandtoxicityofamyloidboligomers
AT fisherk proteolyticsheddingoftheprionproteinviaactivationofmetallopeptidaseadam10reducescellularbindingandtoxicityofamyloidboligomers
AT jonesa proteolyticsheddingoftheprionproteinviaactivationofmetallopeptidaseadam10reducescellularbindingandtoxicityofamyloidboligomers
AT baronj proteolyticsheddingoftheprionproteinviaactivationofmetallopeptidaseadam10reducescellularbindingandtoxicityofamyloidboligomers
AT howellg proteolyticsheddingoftheprionproteinviaactivationofmetallopeptidaseadam10reducescellularbindingandtoxicityofamyloidboligomers
AT cowleys proteolyticsheddingoftheprionproteinviaactivationofmetallopeptidaseadam10reducescellularbindingandtoxicityofamyloidboligomers
AT chintawars proteolyticsheddingoftheprionproteinviaactivationofmetallopeptidaseadam10reducescellularbindingandtoxicityofamyloidboligomers
AT caderm proteolyticsheddingoftheprionproteinviaactivationofmetallopeptidaseadam10reducescellularbindingandtoxicityofamyloidboligomers
AT kellettk proteolyticsheddingoftheprionproteinviaactivationofmetallopeptidaseadam10reducescellularbindingandtoxicityofamyloidboligomers
AT hoopern proteolyticsheddingoftheprionproteinviaactivationofmetallopeptidaseadam10reducescellularbindingandtoxicityofamyloidboligomers